Suppr超能文献

辛伐他汀通过减轻炎症反应预防大鼠肺动脉高压的发生。

[Simvastatin prevents the development of pulmonary hypertension in the rats through reduction of inflammation].

作者信息

Zhang Wei-Hua, Lu Wei-Xuan, Zhang Yun-Jian, Ji Ying-Qun, Liu Chun-Ping, Li Guo

机构信息

Department of Respiratory Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2009 Mar 31;89(12):855-9.

Abstract

OBJECTIVE

To investigate the protection of simvastatin on monocrotaline (MCT)-induce pulmonary hypertension (PH) and the mechanism thereof.

METHODS

Thirty-two male Sprague-Dawley rats were randomly divided into 4 equal groups: PH group undergoing subcutaneous injection of MCT and then gastric infusion of normal saline (NS) once a day for 21 days, simvastatin control group undergoing subcutaneous injection of NS and then gastric infusion of simvastatin 2 microg/g once a day for 21 days, simvastatin intervention group undergoing subcutaneous injection of MTS and then gastric infusion of simvastatin 2 microg/g once a day for 21 days, and control group undergoing subcutaneous injection and gastric infusion of NS. Three weeks later the mean pulmonary arterial pressure (mPAP) was detected by right heart catheter. Then the rats were killed with their lungs taken out. Arterial wall area/vessel area (W/V), and arterial wall thickness/vessel external diameter (T/D) were calculated. Perivascular inflammation was scored with the subjective scale of 0 (no) to 4 (severe). Pulmonary interleukin (IL)-6, tumor necrosis factor alpha (TNF-alpha), and monocyte chemotactic protein 1 (MCP-1) were tested by ELISA.

RESULTS

The mPAP of the simvastatin intervention group was (23 +/- 7) mm Hg, significantly lower than that of the PH group [(34 +/- 9) mm Hg, P < 0.05], but not significantly different from that of the normal control group [(20 +/- 4) mm Hg, P > 0.05]. The W/V and T/D of the simvastatin intervention group were 0.442 +/- 0.061 and 0.325 +/- 0.045 respectively, significantly lower than those of the PH group (0.560 +/- 0.086 and 0.368 +/- 0.055 respectively, P < 0.01 and P < 0.05). The perivascular inflammation score of the simvastatin intervention group was (2.19 +/- 0.81), significantly lower than that of the PH group (3.40 +/- 0.65, P < 0.05), and the IL-6, TNF-alpha, and MCP-1 levels of the simvastatin intervention group [(264 +/- 127), (179 +/- 91), and (697 +/- 211) pg/ml respectively] were all significantly lower than those of the PH group [(765 +/- 179), (447 +/- 86), (4428 +/- 757) pg/ml respectively, all P < 0.01].

CONCLUSION

The protective effects of simvastatin against MCT-induced PH may be associated with the inhibition of the perivascular inflammation and lung IL-6, TNF-alpha, and MCP-1 levels.

摘要

目的

探讨辛伐他汀对野百合碱(MCT)诱导的肺动脉高压(PH)的保护作用及其机制。

方法

将32只雄性Sprague-Dawley大鼠随机分为4组,每组8只:PH组皮下注射MCT,随后每天经胃灌注生理盐水(NS),共21天;辛伐他汀对照组皮下注射NS,随后每天经胃灌注2μg/g辛伐他汀,共21天;辛伐他汀干预组皮下注射MCT,随后每天经胃灌注2μg/g辛伐他汀,共21天;对照组皮下注射及经胃灌注NS。3周后,通过右心导管检测平均肺动脉压(mPAP)。然后处死大鼠并取出肺组织。计算动脉壁面积/血管面积(W/V)和动脉壁厚度/血管外径(T/D)。采用主观评分法对血管周围炎症进行评分,范围为0(无)至4(重度)。通过酶联免疫吸附测定法(ELISA)检测肺组织白细胞介素(IL)-6、肿瘤坏死因子α(TNF-α)和单核细胞趋化蛋白1(MCP-1)水平。

结果

辛伐他汀干预组的mPAP为(23±7)mmHg,显著低于PH组[(34±9)mmHg,P<0.05],但与正常对照组[(20±4)mmHg,P>0.05]相比差异无统计学意义。辛伐他汀干预组的W/V和T/D分别为0.442±0.061和0.325±0.045,显著低于PH组(分别为0.560±0.086和0.368±0.055,P<0.01和P<0.05)。辛伐他汀干预组的血管周围炎症评分为(2.19±0.81),显著低于PH组(3.40±0.65,P<0.05),且辛伐他汀干预组的IL-6、TNF-α和MCP-1水平[分别为(264±127)、(179±91)和(697±211)pg/ml]均显著低于PH组[分别为(765±179)、(447±86)、(4428±757)pg/ml,均P<0.01]。

结论

辛伐他汀对MCT诱导的PH的保护作用可能与抑制血管周围炎症及肺组织IL-6、TNF-α和MCP-1水平有关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验